Indian dermatological experts’ opinion on clotrimazole dusting powder in superficial fungal infection

Authors

  • Manjunath Shenoy Department of Dermatology, Yenepoya Medical College, Mangalore, Karnataka, India
  • Anil Ganjoo Skinnovation Clinics, Delhi, India
  • Kiran Godse Department of Dermatology, D. Y. Patil Hospital and School of Medicine, Navi Mumbai, Maharashtra, India
  • Sunil Ghate Dr Ghate’s Skin, Hair and LASER Center, Mumbai, Maharashtra, India
  • Ravi Vadrevu Department of Dermatology, Kakinada, Andhra Pradesh, India
  • Pallavi Mishra Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, India
  • Dhiraj Dhoot Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, India
  • Saiprasad Patil Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262318

Keywords:

Indian dermatological, Clotrimazole, Superficial fungal infection

Abstract

Dermatophytosis is among the most common skin infections in India and continues to pose a major therapeutic challenge because of increasing chronicity, recurrence, and partial treatment response. Recent years have witnessed significant epidemiological and mycological changes, including the emergence of multidrug-resistant T. mentagrophytes/T. interdigitale complex. In addition to pathogen-related factors, excessive sweating, humidity, occlusion, and skin maceration contribute substantially to persistence and relapse by creating an environment favourable for fungal growth.

References

Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options. Indian J Dermatol Venereol Leprol. 2021;87:468-82.

Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014;117(3):611-7.

Ongsri P, Bunyaratavej S, Leeyaphan C, Pattanaprichakul P, Ongmahutmongkol P, Ariyatanasuporn N, et al. Efficacy of antifungal cream versus powder in the treatment of fungal foot skin infection and unpleasant foot odor at medical department of Thai Naval Rating School. Southeast Asian J Trop Med Public Health. 2018;49(2):297-303.

Desomchoke R, Bunyaratavej S, Leeyaphan C. Efficacy and safety of 1% clotrimazole powder, adjuvant therapy in patients with superficial fungal cutaneous infection in intertriginous areas. J Med Assoc Thai. 2016; 99(12):1355-9.

Jagia R, Mishra P, Dhoot D. Clotrimazole dusting powder improves patient-reported outcomes in patients with dermatophytosis: real world analysis from India. J Dermatol Res. 2026;7(1):1-3.

Ongsri P, Bangchang NN, Saengthong-Aram P, Leeyaphan C, Pattanaprichakul P, Bunyaratavej S. Efficacy of 1% Clotrimazole Powder Monotherapy for Treating Tinea Cruris: A Comparative Randomized Study. Mil Med. 2024;189(12):e2494-8.

Balamuruganvelu S, Reddy SV, Babu G. Age and Genderwise Seasonal Distribution of Dermatophytosis in a Tertiary Care Hospital, Puducherry, India. J Clin of Diagn Res. 2019;13(2):WC06-10.

Downloads

Published

2026-07-01

How to Cite

Shenoy, M., Ganjoo, A., Godse, K., Ghate, S., Vadrevu, R., Mishra, P., Dhoot, D., & Patil, S. (2026). Indian dermatological experts’ opinion on clotrimazole dusting powder in superficial fungal infection. International Journal of Research in Dermatology. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262318

Issue

Section

Letter to the Editor